Guzal Mullabaeva
Guzal Mullabaeva has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Shohista Mukhamedova
Республиканский Специализированный Научно-Практический Медицинский Центр Кардиологии
5 shared publications - N. M. U. Sultanbaeva
Institute of Pharmaceutical Education and Research
3 shared publications - И Шарипов
Республиканский специализированный кардиологический научно-практический центр
3 shared publications Shakhnoz Umarova
Department of Pharmaceutical Management and Economy, PhD, professor, Institute of Pharmaceutical Education and Research, Tashkent, Republic of Uzbekistan
2 shared publications- Д Жуманиязов
Республиканского центра экстренной медицинской помощи
2 shared publications - О Жаббаров
Республиканский специализированный кардиологический научно-практический центр
2 shared publications
Latest Publications
- 14 October 2026
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 26, 1-16
Cost-effectiveness of Empagliflozin in Chronic Heart Failure: A Markov Model-based Analysis in Uzbekistan
Introduction: Chronic Heart Failure (CHF) is a major public health challenge associated with high morbidity, mortality, and healthcare costs. Empagliflozin has demonstrated clinical benefits across the spectrum of heart failure; however, evidence on its economic value in low- and middle-income countries remains limited. To evaluate the cost-effectiveness of adding empagliflozin to standard therapy for patients with chronic heart failure from the perspective of the healthcare payer. Materials and Methods: A cohort-based Markov model with a 3-month cycle length and a 20- year time horizon was developed to simulate disease progression in CHF. Health states included no complications, cardiovascular complications, renal complications, and death. Outcomes were measured in Life Years (LYs), Quality-Adjusted Life Years (QALYs), total costs, and Incremental Cost-Effectiveness Ratios (ICERs). Both deterministic and probabilistic sensitivity analyses were conducted. Results: Quality-adjusted life expectancy increased from 11.595 to 12.224 QALYs. Total discounted costs were 48,133,588 UZS for empagliflozin versus 43,261,361 UZS for standard therapy. The Incremental Cost-Effectiveness Ratio (ICER) was 7,738,951 UZS per QALY gained, which was substantially below the national willingness-to-pay threshold of 141.6 million UZS. Discussions: Since the ICER for empagliflozin compared with placebo is substantially lower than the calculated willingness-to-pay threshold, empagliflozin can be considered a costeffective treatment option. Conclusions: Adding empagliflozin to standard therapy for CHF is a cost-effective intervention in the Republic of Uzbekistan and provides meaningful clinical and economic benefits.
- 14 October 2026
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 26, 1-16
Cost-effectiveness of Empagliflozin in Chronic Heart Failure: A Markov Model-based Analysis in Uzbekistan
Introduction: Chronic Heart Failure (CHF) is a major public health challenge associated with high morbidity, mortality, and healthcare costs. Empagliflozin has demonstrated clinical benefits across the spectrum of heart failure; however, evidence on its economic value in low- and middle-income countries remains limited. To evaluate the cost-effectiveness of adding empagliflozin to standard therapy for patients with chronic heart failure from the perspective of the healthcare payer. Materials and Methods: A cohort-based Markov model with a 3-month cycle length and a 20- year time horizon was developed to simulate disease progression in CHF. Health states included no complications, cardiovascular complications, renal complications, and death. Outcomes were measured in Life Years (LYs), Quality-Adjusted Life Years (QALYs), total costs, and Incremental Cost-Effectiveness Ratios (ICERs). Both deterministic and probabilistic sensitivity analyses were conducted. Results: Quality-adjusted life expectancy increased from 11.595 to 12.224 QALYs. Total discounted costs were 48,133,588 UZS for empagliflozin versus 43,261,361 UZS for standard therapy. The Incremental Cost-Effectiveness Ratio (ICER) was 7,738,951 UZS per QALY gained, which was substantially below the national willingness-to-pay threshold of 141.6 million UZS. Discussions: Since the ICER for empagliflozin compared with placebo is substantially lower than the calculated willingness-to-pay threshold, empagliflozin can be considered a costeffective treatment option. Conclusions: Adding empagliflozin to standard therapy for CHF is a cost-effective intervention in the Republic of Uzbekistan and provides meaningful clinical and economic benefits.
- 9 April 2026
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 22
Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure and Chronic Kidney Disease: A Systematic Review
Introduction: To evaluate the cost-effectiveness of empagliflozin in patients with chronic heart failure with preserved ejection fraction (CHFpEF) and moderately reduced ejection fraction (CHFmrEF) across various healthcare systems. Materials and Methods: A systematic review was conducted according to PRISMA 2024 guidelines. A total of 6 studies were included after screening 225 records from PubMed, Web of Science, ScienceDirect, and Google Scholar. Studies evaluating cost-effectiveness outcomes, including incremental cost-effectiveness ratios (ICER), quality-adjusted life years (QALY), and healthcare costs, were analyzed. Results: All included studies applied a Markov model over a 10-year time horizon. Empagliflozin was associated with a 15–18% reduction in hospitalizations, an increase in QALYs by 0.11–0.67, and ICERs ranging from €5,089/QALY to $174,053/QALY, depending on the healthcare setting and model assumptions. Examples include: Spain: €5,089/QALY, China: $11,292/QALY, USA: $25,974–$174,053/QALY, Australia: A$29,202/QALY. ICER per life year (LY) ranged from $6,246 to $151,929, indicating variable cost-effectiveness based on country-specific cost structures and thresholds. Conclusions: Empagliflozin appears to be a cost-effective add-on therapy to standard care for CHFpEF and CHFmrEF, especially in healthcare systems with high hospitalization costs. However, its value is highly sensitive to drug pricing and national willingness-to-pay thresholds. Further real-world studies are needed to confirm long-term economic benefits. The review was registered with PROSPERO (CRD420250654439). Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420250654439.
- 9 April 2026
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 22
Cost-Effectiveness of Empagliflozin in Patients with Chronic Heart Failure and Chronic Kidney Disease: A Systematic Review
Introduction: To evaluate the cost-effectiveness of empagliflozin in patients with chronic heart failure with preserved ejection fraction (CHFpEF) and moderately reduced ejection fraction (CHFmrEF) across various healthcare systems. Materials and Methods: A systematic review was conducted according to PRISMA 2024 guidelines. A total of 6 studies were included after screening 225 records from PubMed, Web of Science, ScienceDirect, and Google Scholar. Studies evaluating cost-effectiveness outcomes, including incremental cost-effectiveness ratios (ICER), quality-adjusted life years (QALY), and healthcare costs, were analyzed. Results: All included studies applied a Markov model over a 10-year time horizon. Empagliflozin was associated with a 15–18% reduction in hospitalizations, an increase in QALYs by 0.11–0.67, and ICERs ranging from €5,089/QALY to $174,053/QALY, depending on the healthcare setting and model assumptions. Examples include: Spain: €5,089/QALY, China: $11,292/QALY, USA: $25,974–$174,053/QALY, Australia: A$29,202/QALY. ICER per life year (LY) ranged from $6,246 to $151,929, indicating variable cost-effectiveness based on country-specific cost structures and thresholds. Conclusions: Empagliflozin appears to be a cost-effective add-on therapy to standard care for CHFpEF and CHFmrEF, especially in healthcare systems with high hospitalization costs. However, its value is highly sensitive to drug pricing and national willingness-to-pay thresholds. Further real-world studies are needed to confirm long-term economic benefits. The review was registered with PROSPERO (CRD420250654439). Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420250654439.
- 17 March 2026
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 22
Clinical efficacy of SGLT2 inhibitors in chronic heart failure and chronic kidney disease: a systematic review and meta-analysis
Introduction: Chronic heart failure (CHF) and chronic kidney disease (CKD) pose a significant medical burden, contributing to increased mortality and hospitalization rates. Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed for the treatment of type 2 diabetes mellitus; however, recent studies have demonstrated their cardiorenal protective effects. This systematic review aims to evaluate the impact of empagliflozin on CKD progression in patients with CHF across different ejection fractions. Methods: A systematic literature search was conducted in PubMed, Web of Science, ScienceDirect, and Google Scholar for studies published between 2010 and 2024. The analysis included randomized controlled trials comparing empagliflozin with placebo in patients with both CHF and CKD. The primary outcomes assessed were cardiovascular mortality, hospitalization rates, and CKD progression. Results: A meta-analysis of 14 studies (n = 27,792) revealed a significant reduction in cardiovascular mortality (OR = 0.76, 95% CI: 0.70–0.82), hospitalization rates (OR = 0.74, 95% CI: 0.70–0.79), and CKD progression (OR = 0.80, 95% CI: 0.74–0.87). Conclusions: Empagliflozin exhibits significant cardiorenal protective effects, independent of diabetes status. Its use is warranted to mitigate cardiovascular and renal risks in patients with CHF and CKD. Further research is needed to investigate its long-term effects. This systematic review is registered in the open-access registry PROSPERO (2025, CRD420250652303).
- 17 March 2026
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 22
Clinical efficacy of SGLT2 inhibitors in chronic heart failure and chronic kidney disease: a systematic review and meta-analysis
Introduction: Chronic heart failure (CHF) and chronic kidney disease (CKD) pose a significant medical burden, contributing to increased mortality and hospitalization rates. Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed for the treatment of type 2 diabetes mellitus; however, recent studies have demonstrated their cardiorenal protective effects. This systematic review aims to evaluate the impact of empagliflozin on CKD progression in patients with CHF across different ejection fractions. Methods: A systematic literature search was conducted in PubMed, Web of Science, ScienceDirect, and Google Scholar for studies published between 2010 and 2024. The analysis included randomized controlled trials comparing empagliflozin with placebo in patients with both CHF and CKD. The primary outcomes assessed were cardiovascular mortality, hospitalization rates, and CKD progression. Results: A meta-analysis of 14 studies (n = 27,792) revealed a significant reduction in cardiovascular mortality (OR = 0.76, 95% CI: 0.70–0.82), hospitalization rates (OR = 0.74, 95% CI: 0.70–0.79), and CKD progression (OR = 0.80, 95% CI: 0.74–0.87). Conclusions: Empagliflozin exhibits significant cardiorenal protective effects, independent of diabetes status. Its use is warranted to mitigate cardiovascular and renal risks in patients with CHF and CKD. Further research is needed to investigate its long-term effects. This systematic review is registered in the open-access registry PROSPERO (2025, CRD420250652303).
- Open Access
- 30 June 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (2) , 159-168
To‘satdan yurak o‘limining prediktorlari va aortokoronar shuntlash operatsiyasini ularning rivojlanishiga ta’siri
Sudden Cardiac Death (SCD) is one of the most severe and life-threatening manifestations of cardiovascular diseases and is among the leading causes of mortality worldwide. The primary pathogenic factors contributing to the development of this condition include ischemic heart disease (IHD), ventricular arrhythmias, reduced left ventricular ejection fraction (LVEF), and the formation of scar tissue in the myocardium. The mechanism underlying SCD is complex, involving a combination of myocardial ischemia, electrical instability, and morphological changes, all of which contribute to the onset of malignant arrhythmias. Coronary artery bypass grafting (CABG) is an effective revascularization technique in patients with ischemic heart disease. It not only alleviates symptoms but also significantly improves long-term prognosis by enhancing cardiac function. Studies have shown that CABG, particularly in patients with reduced LVEF, decreases overall mortality and the risk of developing SCD. In conclusion, CABG plays an important role in the prevention of SCD, but it is not a standalone solution. A thorough analysis of the underlying risk factors, early identification of high-risk patients, and the development of individualized, comprehensive preventive and therapeutic strategies represent the most effective approach in reducing SCD incidence.
- 30 June 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (2) , 159-168
Open AccessTo‘satdan yurak o‘limining prediktorlari va aortokoronar shuntlash operatsiyasini ularning rivojlanishiga ta’siri
Sudden Cardiac Death (SCD) is one of the most severe and life-threatening manifestations of cardiovascular diseases and is among the leading causes of mortality worldwide. The primary pathogenic factors contributing to the development of this condition include ischemic heart disease (IHD), ventricular arrhythmias, reduced left ventricular ejection fraction (LVEF), and the formation of scar tissue in the myocardium. The mechanism underlying SCD is complex, involving a combination of myocardial ischemia, electrical instability, and morphological changes, all of which contribute to the onset of malignant arrhythmias. Coronary artery bypass grafting (CABG) is an effective revascularization technique in patients with ischemic heart disease. It not only alleviates symptoms but also significantly improves long-term prognosis by enhancing cardiac function. Studies have shown that CABG, particularly in patients with reduced LVEF, decreases overall mortality and the risk of developing SCD. In conclusion, CABG plays an important role in the prevention of SCD, but it is not a standalone solution. A thorough analysis of the underlying risk factors, early identification of high-risk patients, and the development of individualized, comprehensive preventive and therapeutic strategies represent the most effective approach in reducing SCD incidence.
- Open Access
- 30 June 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (2) , 145-151
Систематический обзор хирургии клапанов сердца с непрерывной коронарной перфузией на работающем сердце у пациентов с низкой фракцией выброса левого желудочка.
Aim. Beating-heart continuous coronary perfusion (BHCCP) is an alternative to cardioplegic arrest in valve surgery, potentially reducing ischemic reperfusion injury, especially in high-risk patients with low left ventricular ejection fraction (LVEF). Materials and methods. A systematic review of prospective and observational studies was conducted, focusing on BHCCP versus cardioplegia in valve surgery, with emphasis on patients with LVEF <35%. Results. Studies (e.g., Matsumoto et al., 2002) showed no significant difference in mortality or major complications, but BHCCP reduced myocardial damage markers (e.g., Troponin I, CK-MB) by 20–40% compared to cardioplegia. Clinical outcomes remained comparable across groups. Conclusion. BHCCP is a safe alternative to cardioplegia, with potential benefits in myocardial protection, though high-quality randomized trials are needed to confirm clinical superiority.
- 30 June 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (2) , 145-151
Open AccessСистематический обзор хирургии клапанов сердца с непрерывной коронарной перфузией на работающем сердце у пациентов с низкой фракцией выброса левого желудочка.
Aim. Beating-heart continuous coronary perfusion (BHCCP) is an alternative to cardioplegic arrest in valve surgery, potentially reducing ischemic reperfusion injury, especially in high-risk patients with low left ventricular ejection fraction (LVEF). Materials and methods. A systematic review of prospective and observational studies was conducted, focusing on BHCCP versus cardioplegia in valve surgery, with emphasis on patients with LVEF <35%. Results. Studies (e.g., Matsumoto et al., 2002) showed no significant difference in mortality or major complications, but BHCCP reduced myocardial damage markers (e.g., Troponin I, CK-MB) by 20–40% compared to cardioplegia. Clinical outcomes remained comparable across groups. Conclusion. BHCCP is a safe alternative to cardioplegia, with potential benefits in myocardial protection, though high-quality randomized trials are needed to confirm clinical superiority.
- Open Access
- 30 March 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (1) , 4-10
Сравнение эффективности оригинальной и генерической формы клопидогреля у больных с ИБС
Background. To evaluate the antiaggregation activity and clinical tolerability of Areplex (75 mg, ADAMED, Poland) compared to Plavix (75 mg, Sanofi-Winthrop Industrie, France) in CAD patients. Materials and methods. A blinded, randomized, two-parallel-group study included 40 patients with stable angina (FC I-IV). Platelet aggregation was assessed using the AP 2110 analyzer (SOLAR) with ADP (5 µmol/L) and arachidonic acid (0.5 mg/mL) inducers after a 300 mg loading dose. Results. At 24 hours post-dose, both groups showed significant reductions in aggregation degree and rate (p0.05). Safety profiles were comparable, with no adverse events reported. Conclusion. Areplex demonstrated bioequivalence to Plavix, with good tolerability, supporting its use as an effective antiplatelet agent in CAD patients.
- 30 March 2025
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 2 (1) , 4-10
Open AccessСравнение эффективности оригинальной и генерической формы клопидогреля у больных с ИБС
Background. To evaluate the antiaggregation activity and clinical tolerability of Areplex (75 mg, ADAMED, Poland) compared to Plavix (75 mg, Sanofi-Winthrop Industrie, France) in CAD patients. Materials and methods. A blinded, randomized, two-parallel-group study included 40 patients with stable angina (FC I-IV). Platelet aggregation was assessed using the AP 2110 analyzer (SOLAR) with ADP (5 µmol/L) and arachidonic acid (0.5 mg/mL) inducers after a 300 mg loading dose. Results. At 24 hours post-dose, both groups showed significant reductions in aggregation degree and rate (p0.05). Safety profiles were comparable, with no adverse events reported. Conclusion. Areplex demonstrated bioequivalence to Plavix, with good tolerability, supporting its use as an effective antiplatelet agent in CAD patients.
- Open Access
- 27 September 2024
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 1 (3) , 188-195
Влияние реваскуляризации миокарда на нейрогормональные и гемодинамические параметры у больных с остром миокардным инфарктом
Цель. Острый инфаркт миокарда (ОИМ) остается основной причиной заболеваемости и смерт- ности в мире. Влияние реваскуляризации миокарда на уровень нейрогормонов и гемодинамику у больных с ОИМ остается важной темой для клинических исследований. Материалы и методы. В исследование было включено 120 пациентов с острым коронарным синдромом с подъемом сегмента ST (ОКСспST). Средний возраст составил 52,9±8,9 лет. Пациенты были разделены на две группы: группа I (89 пациентов), не подвергавшихся реваску- ляризации, и группа II (31 пациент), перенесших перкутанную коронарную интервенцию (ЧКВ) с установкой стента. В исследовании оценивались нейрогормоны NTproBNP и растворимый фермент ST2, а также эхокардиографические параметры на 10-14-й день после госпитализации. Результаты. Анализ нейрогормонов показал, что уровень NTproBNP не отличался между группами. Однако уровень NTproBNP был ниже в группе с ЧКВ по сравнению с группой без реваскуляризации. Уровень ST2 был значительно ниже в группе с ЧКВ (130,8±48,6 ng/ml) по сравнению с группой без реваскуляризации (196,8±58,2 ng/ml) (p<0,05). Гемодинамические параметры, такие как конечный диастолический объем (КДО) и конечный систолический объем (КСО), были значительно ниже в группе с ЧКВ. Заключение. Реваскуляризация миокарда, в частности стентирование инфаркт-связанной артерии, значительно улучшает нейрогормональные параметры, особенно уровень раствори- мого ST2, и положительно влияет на гемодинамические параметры, что привело к лучшим результатам у пациентов, перенесших ЧКВ.
- 27 September 2024
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 1 (3) , 188-195
Open AccessВлияние реваскуляризации миокарда на нейрогормональные и гемодинамические параметры у больных с остром миокардным инфарктом
Цель. Острый инфаркт миокарда (ОИМ) остается основной причиной заболеваемости и смерт- ности в мире. Влияние реваскуляризации миокарда на уровень нейрогормонов и гемодинамику у больных с ОИМ остается важной темой для клинических исследований. Материалы и методы. В исследование было включено 120 пациентов с острым коронарным синдромом с подъемом сегмента ST (ОКСспST). Средний возраст составил 52,9±8,9 лет. Пациенты были разделены на две группы: группа I (89 пациентов), не подвергавшихся реваску- ляризации, и группа II (31 пациент), перенесших перкутанную коронарную интервенцию (ЧКВ) с установкой стента. В исследовании оценивались нейрогормоны NTproBNP и растворимый фермент ST2, а также эхокардиографические параметры на 10-14-й день после госпитализации. Результаты. Анализ нейрогормонов показал, что уровень NTproBNP не отличался между группами. Однако уровень NTproBNP был ниже в группе с ЧКВ по сравнению с группой без реваскуляризации. Уровень ST2 был значительно ниже в группе с ЧКВ (130,8±48,6 ng/ml) по сравнению с группой без реваскуляризации (196,8±58,2 ng/ml) (p<0,05). Гемодинамические параметры, такие как конечный диастолический объем (КДО) и конечный систолический объем (КСО), были значительно ниже в группе с ЧКВ. Заключение. Реваскуляризация миокарда, в частности стентирование инфаркт-связанной артерии, значительно улучшает нейрогормональные параметры, особенно уровень раствори- мого ST2, и положительно влияет на гемодинамические параметры, что привело к лучшим результатам у пациентов, перенесших ЧКВ.
- Open Access
- 27 September 2024
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 1 (3) , 179-187
Фенотипические характеристики пациентов с хронической сердечной недостаточностью и сохраненной фракцией выброса в сочетании с хронической болезнью почек
Цель. Сердечная недостаточность с сохраненной фракцией выброса (СНсФВ) представляет собой сложное клиническое состояние, часто ассоциированное с хронической болезнью почек (ХБП). Взаимосвязь между этими двумя заболеваниями остаётся малоизученной. Цель данного исследования — исследовать фенотипические характеристики пациентов с СНсФВ в сочетании с ХБП, с акцентом на изменения биомаркеров и клинические исходы. Материалы и методы. В исследование были включены 200 пациентов с диагнозом СНсФВ (фракция выброса ≥50%) и ХБП стадий 1-3б. Были собраны клинические данные, а также изме- рены различные биомаркеры, включая NT-proBNP, цистатин С и микроальбуминурию (МАУ), с использованием иммунохемилюминесцентного анализа (COBAS e411, Roche HITACHI), флуоресцентного иммуноанализа (анализатор Finecare III PLUS) и турбодиметрического тестирования (анализатор Mindray BS-380), соответственно. Оценка СКФ проводилась с использованием формулы CKD-EPI. Результаты. Результаты показали более высокую распространенность диабета 2 типа (СД2) и фибрилляции предсердий (ФП) среди пациентов с ХБП 3б стадии. Напротив, пациенты с ХБП 3а имели худший контроль уровня липидов в крови. Примечательно, что снижение СКФ было значительно связано с повышением уровней креатинина, цистатина С и МАУ. У пациентов с ХБП стадий 1-2, несмотря на нормальные уровни креатинина, уровни цистатина С и МАУ превышали норму. Заключение. Среди пациентов с СНсФВ чаще встречалась ХБП 2 стадии в сочетании с ожире- нием, при этом, несмотря на относительно нормальные значения СКФ, наблюдались изменения других почечных маркеров, таких как цистатин С и МАУ. Это подчеркивает важность раннего выявления и лечения почечной недостаточности у пациентов с СНсФВ, акцентируя внимание на необходимости комплексного подхода к лечению заболеваний сердца и почек.
- 27 September 2024
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 1 (3) , 179-187
Open AccessФенотипические характеристики пациентов с хронической сердечной недостаточностью и сохраненной фракцией выброса в сочетании с хронической болезнью почек
Цель. Сердечная недостаточность с сохраненной фракцией выброса (СНсФВ) представляет собой сложное клиническое состояние, часто ассоциированное с хронической болезнью почек (ХБП). Взаимосвязь между этими двумя заболеваниями остаётся малоизученной. Цель данного исследования — исследовать фенотипические характеристики пациентов с СНсФВ в сочетании с ХБП, с акцентом на изменения биомаркеров и клинические исходы. Материалы и методы. В исследование были включены 200 пациентов с диагнозом СНсФВ (фракция выброса ≥50%) и ХБП стадий 1-3б. Были собраны клинические данные, а также изме- рены различные биомаркеры, включая NT-proBNP, цистатин С и микроальбуминурию (МАУ), с использованием иммунохемилюминесцентного анализа (COBAS e411, Roche HITACHI), флуоресцентного иммуноанализа (анализатор Finecare III PLUS) и турбодиметрического тестирования (анализатор Mindray BS-380), соответственно. Оценка СКФ проводилась с использованием формулы CKD-EPI. Результаты. Результаты показали более высокую распространенность диабета 2 типа (СД2) и фибрилляции предсердий (ФП) среди пациентов с ХБП 3б стадии. Напротив, пациенты с ХБП 3а имели худший контроль уровня липидов в крови. Примечательно, что снижение СКФ было значительно связано с повышением уровней креатинина, цистатина С и МАУ. У пациентов с ХБП стадий 1-2, несмотря на нормальные уровни креатинина, уровни цистатина С и МАУ превышали норму. Заключение. Среди пациентов с СНсФВ чаще встречалась ХБП 2 стадии в сочетании с ожире- нием, при этом, несмотря на относительно нормальные значения СКФ, наблюдались изменения других почечных маркеров, таких как цистатин С и МАУ. Это подчеркивает важность раннего выявления и лечения почечной недостаточности у пациентов с СНсФВ, акцентируя внимание на необходимости комплексного подхода к лечению заболеваний сердца и почек.
- Open Access
- 27 September 2024
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 1 (3) , 188-195
Влияние реваскуляризации миокарда на нейрогормональные и гемодинамические параметры у больных с остром миокардным инфарктом
Background. Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality worldwide. The impact of myocardial revascularization on neurohormonal levels and hemodynamics in patients with AMI remains a topic of significant clinical interest. Materials and methods. This study included 120 patients diagnosed with acute coronary syndrome with ST-segment elevation (ACSspST), with a mean age of 52.9±8.9 years. Patients were divided into two groups: Group I (89 patients) who did not undergo revascularization, and Group II (31 patients) who underwent percutaneous coronary intervention (PCI) with stenting. The study assessed neurohormonal markers NTproBNP and soluble ST2, along with echocardiographic parameters, on days 10-14 post-admission. Results. The analysis of neurohormonal levels showed no significant difference in NTproBNP levels between the two groups. However, the NTproBNP levels were lower in the PCI group compared to the non-revascularized group. In contrast, the ST2 levels were significantly lower in the PCI group (130.8±48.6 ng/ml) compared to the non-revascularized group (196.8±58.2 ng/ml) (p<0.05). Hemodynamic parameters, such as left ventricular end-diastolic volume (EDV) and end-systolic volume (ESV), were significantly lower in the PCI group. Conclusion. Myocardial revascularization, specifically coronary stenting, significantly improved neurohormonal parameters, particularly the soluble ST2 levels, and positively affected hemodynamic parameters, demonstrating better outcomes in patients who underwent PCI.
- 27 September 2024
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 1 (3) , 188-195
Open AccessВлияние реваскуляризации миокарда на нейрогормональные и гемодинамические параметры у больных с остром миокардным инфарктом
Background. Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality worldwide. The impact of myocardial revascularization on neurohormonal levels and hemodynamics in patients with AMI remains a topic of significant clinical interest. Materials and methods. This study included 120 patients diagnosed with acute coronary syndrome with ST-segment elevation (ACSspST), with a mean age of 52.9±8.9 years. Patients were divided into two groups: Group I (89 patients) who did not undergo revascularization, and Group II (31 patients) who underwent percutaneous coronary intervention (PCI) with stenting. The study assessed neurohormonal markers NTproBNP and soluble ST2, along with echocardiographic parameters, on days 10-14 post-admission. Results. The analysis of neurohormonal levels showed no significant difference in NTproBNP levels between the two groups. However, the NTproBNP levels were lower in the PCI group compared to the non-revascularized group. In contrast, the ST2 levels were significantly lower in the PCI group (130.8±48.6 ng/ml) compared to the non-revascularized group (196.8±58.2 ng/ml) (p<0.05). Hemodynamic parameters, such as left ventricular end-diastolic volume (EDV) and end-systolic volume (ESV), were significantly lower in the PCI group. Conclusion. Myocardial revascularization, specifically coronary stenting, significantly improved neurohormonal parameters, particularly the soluble ST2 levels, and positively affected hemodynamic parameters, demonstrating better outcomes in patients who underwent PCI.
- Open Access
- 27 September 2024
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 1 (3) , 179-187
Фенотипические характеристики пациентов с хронической сердечной недостаточностью и сохраненной фракцией выброса в сочетании с хронической болезнью почек
Background. Heart failure with preserved ejection fraction (HFpEF) is a complex clinical condition, often associated with chronic kidney disease (CKD). The interplay between these two conditions remains underexplored. This study aims to examine the phenotypic characteristics of patients with HFpEF in conjunction with CKD, with a focus on biomarker alterations and clinical outcomes. Materials and methods. The study enrolled 200 patients diagnosed with both HFpEF (ejection fraction ≥50%) and CKD stages 1-3b. Clinical data were collected, and various biomarkers, including NT-proBNP, cystatin C, and microalbuminuria (MAU), were measured using chemiluminescent immunoassay (COBAS e411, Roche HITACHI), fluorescent immunoassay (Finecare III PLUS analyzer), and turbidimetric testing (Mindray BS-380 analyzer), respectively. GFR was calculated using the CKD-EPI formula. Results. The results indicated a higher prevalence of Type 2 diabetes (T2D) and atrial fibrillation (AF) among patients with CKD stage 3b. Conversely, those with CKD stage 3a exhibited worse control over blood lipid levels. Notably, a decrease in GFR was significantly correlated with elevated levels of creatinine, cystatin C, and MAU. In patients with CKD stages 1-2, even though creatinine levels were normal, cystatin C and MAU levels were higher than the normative range. Conclusion. Among HFpEF patients, CKD stage 2 in combination with obesity was more common, with changes observed in renal biomarkers such as cystatin C and MAU, despite relatively normal GFR values. This highlights the importance of early detection and management of renal impairment in HFpEF patients, emphasizing a need for comprehensive cardiac and renal care.
- 27 September 2024
- Published by Republican Specialized Scientific-Practical Medical Center of Cardiology in CARDIOLOGY OF UZBEKISTAN
- Vol. 1 (3) , 179-187
Open AccessФенотипические характеристики пациентов с хронической сердечной недостаточностью и сохраненной фракцией выброса в сочетании с хронической болезнью почек
Background. Heart failure with preserved ejection fraction (HFpEF) is a complex clinical condition, often associated with chronic kidney disease (CKD). The interplay between these two conditions remains underexplored. This study aims to examine the phenotypic characteristics of patients with HFpEF in conjunction with CKD, with a focus on biomarker alterations and clinical outcomes. Materials and methods. The study enrolled 200 patients diagnosed with both HFpEF (ejection fraction ≥50%) and CKD stages 1-3b. Clinical data were collected, and various biomarkers, including NT-proBNP, cystatin C, and microalbuminuria (MAU), were measured using chemiluminescent immunoassay (COBAS e411, Roche HITACHI), fluorescent immunoassay (Finecare III PLUS analyzer), and turbidimetric testing (Mindray BS-380 analyzer), respectively. GFR was calculated using the CKD-EPI formula. Results. The results indicated a higher prevalence of Type 2 diabetes (T2D) and atrial fibrillation (AF) among patients with CKD stage 3b. Conversely, those with CKD stage 3a exhibited worse control over blood lipid levels. Notably, a decrease in GFR was significantly correlated with elevated levels of creatinine, cystatin C, and MAU. In patients with CKD stages 1-2, even though creatinine levels were normal, cystatin C and MAU levels were higher than the normative range. Conclusion. Among HFpEF patients, CKD stage 2 in combination with obesity was more common, with changes observed in renal biomarkers such as cystatin C and MAU, despite relatively normal GFR values. This highlights the importance of early detection and management of renal impairment in HFpEF patients, emphasizing a need for comprehensive cardiac and renal care.